2021
DOI: 10.1186/s13063-021-05675-x
|View full text |Cite
|
Sign up to set email alerts
|

A multi-centre, randomized, double-blind, placebo-controlled clinical trial of the efficacy and safety of chloroquine phosphate, hydroxychloroquine sulphate and lopinavir/ritonavir for the treatment of COVID-19 in Lagos State: study protocol for a randomized controlled trial

Abstract: Background The coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that was first identified in Wuhan, Hubei, China, in December 2019. It was recognized as a pandemic by the World Health Organization on 11 March 2020. Outbreak forecasting and mathematical modelling suggest that these numbers will continue to rise. Early identification of effective remedies that can shorten the duration and severity of illness is critical for Lagos St… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
6
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(6 citation statements)
references
References 35 publications
(28 reference statements)
0
6
0
Order By: Relevance
“…A comprehensive and systematic research about the repurposing of drugs in COVID-19 was conducted by Srivastava and Singh (2021), the results revealed that no drugs passed clinical trials or were approved by the FDA for COVID-19 [23]. In fact, various reports that clinical trials regarding the potential therapeutic possibilities, such as hydroxychloroquine, lopinavir-ritonavir, and ivermectin, showed that choices were unsuccessful in the treatment of COVID-19 patients [24][25][26][27]. Although COVID-19 vaccines were successfully developed and massively distributed, there is a lack of effective treatment [28].…”
Section: Introduction-covid-19 Options For Treatmentmentioning
confidence: 99%
“…A comprehensive and systematic research about the repurposing of drugs in COVID-19 was conducted by Srivastava and Singh (2021), the results revealed that no drugs passed clinical trials or were approved by the FDA for COVID-19 [23]. In fact, various reports that clinical trials regarding the potential therapeutic possibilities, such as hydroxychloroquine, lopinavir-ritonavir, and ivermectin, showed that choices were unsuccessful in the treatment of COVID-19 patients [24][25][26][27]. Although COVID-19 vaccines were successfully developed and massively distributed, there is a lack of effective treatment [28].…”
Section: Introduction-covid-19 Options For Treatmentmentioning
confidence: 99%
“…[ 2 , 3 , 4 , 5 ] It has been suggested as a potential anticancer drug, [6] and for treatment of COVID‐19. [ 1 , 7 , 8 ] Several studies suggested that interactions of chloroquine with DNA might underlie the antimalarial activity of CQP. [6] …”
Section: Introductionmentioning
confidence: 99%
“…This is important to reach at decisions whether malaria developed resistance to this medication and alternative solutions. [ 4 , 7 , 8 ]…”
Section: Introductionmentioning
confidence: 99%
See 2 more Smart Citations